Combinatorial cloning and expression library analysis were used to isolate human antibody Fab fragments specific for the capsular polysaccharide of Streptococcus pneumoniae serotype 23F. Thirty 23F-specific Fabs were isolated from seven vaccinated donors, and the sequences of the heavy (H)-and light (L)-chain variable regions were determined. All individuals utilized either the V A23 L chain, the V L6 L chain, or both chains in forming the 23F-specific combining site. V A23 L chains paired primarily with VH3-23 H chains. V L6 L chains were more promiscuous in heavy-chain usage between individuals. Both H and L chains were mutated, primarily in the complementarity-determining regions, compared to their closest germ line counterpart, suggesting a recall response that has undergone affinity maturation. H-chain isotypes were reflective of those found in the serum. Shared somatic modifications demonstrated that immunoglobulin G2 (IgG2) and IgA antibodies arose from the same somatically matured B cell. Our results indicate that the response to the serotype 23F pneumococcal capsular polysaccharide is oligoclonal within the individual, with one or two paratope families accounting for the majority of expressed antibody. We also determined that, in spite of the combinatorial diversity available to the immune system, the 23F-specific response is highly restricted at the population level, with the same two L-chain-determined paratope families recurring in all individuals. Lastly, analysis of the isolated Fabs indicate all have undergone extensive somatic mutation, as well as class switch, maturational events that presumably require the participation of T cells.Streptococcus pneumoniae is a significant human pathogen causing pneumonia, bacteremia, meningitis, and otitis media. The pathogenic pneumococci are surrounded by a complex capsule composed of polymeric sugars, C polysaccharide, peptidoglycan, and surface proteins. The pneumococcal capsular polysaccharides (PPS), are heterogeneous in structure, with at least 90 different serotypes occurring within the species S. pneumoniae. PPS epitopes are immunogenic in adults and elicit antibodies that protect against infection. A vaccine containing capsular polysaccharides from 23 pneumococcal serotypes (23-valent) is available and is currently recommended for persons over 65 years of age and for other adults considered to be at increased risk of developing pneumococcal disease. Purified capsular polysaccharides do not, however, induce a protective antibody response in infants, who comprise one of the primary populations at risk. Consequently, a 7-valent polysaccharide-protein conjugate vaccine has been developed and shown to be efficacious in infants and has recently been licensed for use in this age group. Capsular polysaccharides are defined as TI-2 (T-cell-independent) antigens based on their repetitive structure and lack of immunogenicity in xid mice and human infants. The serum response to these polysaccharides in adults is oligoclonal and restricted in isotype, with immunog...